Amphastar Pharmaceuticals (AMPH) Accounts Payables (2013 - 2026)

Amphastar Pharmaceuticals' Accounts Payables history runs 14 years deep, the most recent figure standing at $35.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 32.78% year-over-year to $35.5 million in Q1 2026; TTM through Mar 2026 was $35.5 million, a 32.78% decrease from a year earlier, with the FY2025 full-year figure at $148.3 million, down 5.55% from the prior year.
• Accounts Payables retreated to $35.5 million in Q1 2026 per AMPH's latest filing, from $148.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $222.7 million in Q3 2023 and bottomed at $18.8 million in Q2 2023.
• The 5-year median for Accounts Payables is $84.2 million (2022), against an average of $84.6 million.
• Across the five-year window, Accounts Payables jumped 1015.66% in 2023 and plunged 84.69% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $84.2 million in 2022, then rose by 10.83% to $93.4 million in 2023, then soared by 68.22% to $157.1 million in 2024, then fell by 5.55% to $148.3 million in 2025, then tumbled by 76.07% to $35.5 million in 2026.
• Per Business Quant, the three latest AMPH Accounts Payables figures stand at $35.5 million (Q1 2026), $148.3 million (Q4 2025), and $40.5 million (Q3 2025).